BMS-791325

3 Companies Racing to Transform Hepatitis-C Treatment
Motley Fool
Thu, 09/19/13 - 02:58 am
hepatitis C
Gilead
sofosbuvir
AbbVie
Bristol-Myers Squibb
daclatasvir
asunaprevir
BMS-791325
Three Future Winners and One Major Loser in the HCV Wars
Motley Fool
Fri, 07/19/13 - 11:38 am
hepatitis C
AbbVie
Bristol-Myers Squibb
Gilead
Idenix
sofosbuvir
ledipasvir
daclatasvir
asunaprevir
BMS-791325
IDX20963
Bristol Still Playing Catch-Up To Gilead In Hep C Drug Race
TheStreet.com
Tue, 04/23/13 - 11:21 am
Gilead
Bristol-Myers Squibb
hepatitis C
sofosbuvir
daclatasvir
asunaprevir
BMS-791325
Bristol-Myers Hepatitis C Combo Therapy Blunts Disease
Bloomberg
Tue, 04/23/13 - 08:48 am
BMS-791325
Bristol-Myers Squibb
hepatitis C
daclatasvir
asunaprevir
Bristol-Myers Hepatitis C Combo Therapy Shows Promise
Bloomberg
Tue, 11/13/12 - 11:11 am
hepatitis C
Bristol-Myers Squibb
BMS-791325
asunaprevir
declatasvir